- Conditions
- HIV-1-infection
- Interventions
- GS-1219, BVY, Standard of Care
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 113
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HIV-1 Infection
- Interventions
- BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more
- Conditions
- HIV Infections, Renal Transplant Rejection
- Interventions
- BIC/F/TAF 50Mg-200Mg-25Mg Tablet
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 66
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more
- Conditions
- HIV-1-infection
- Interventions
- Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more
- Conditions
- Hiv
- Interventions
- FTC/TAF
- Drug
- Lead sponsor
- Philadelphia Fight
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV-1-infection
- Interventions
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
- Drug
- Lead sponsor
- The Crofoot Research Center, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV-1-infection
- Interventions
- GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 30
- States / cities
- Beverly Hills, California • San Francisco, California • DeLand, Florida + 25 more
- Conditions
- HIV-1
- Interventions
- DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 12 more
- Conditions
- HIV-1
- Interventions
- D/C/F/TAF FDC placebo
- Drug
- Lead sponsor
- Janssen Pharmaceutica N.V., Belgium
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
- Conditions
- HIV, HBV
- Interventions
- E/C/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
- Conditions
- HIV-1 Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- Up to 120 Hours
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Atlanta, Georgia • Memphis, Tennessee
- Conditions
- Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
- Interventions
- ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 4 Weeks to 17 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 7
- States / cities
- Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
- Conditions
- HIV-1-infection
- Interventions
- GS-3242, BVY, Standard of Care
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 21
- States / cities
- Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Hiv, Hormone Therapy
- Interventions
- Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg, Emtricitabine Tenofovir Alafenamide 200/25 mg
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- HIV-1 Infection
- Interventions
- FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 79
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more
- Conditions
- HIV-1
- Interventions
- DRV/COBI FDC placebo tablet, D/C/F/TAF FDC placebo tablets
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
- Conditions
- HIV Infections
- Interventions
- VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 34
- States / cities
- Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more
- Conditions
- HIV-1 Infection
- Interventions
- FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
- Conditions
- ART, HIV
- Interventions
- Biktarvy
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Ft. Pierce, Florida • West Palm Beach, Florida
- Conditions
- HIV-1-infection
- Interventions
- lepetegravir, lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide, lepetegravir/lenacapavir pacfosacil FDC, Placebo to Match BVY, Placebo to Match GS1720/GS-4182 FDC
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more
- Conditions
- HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
- Interventions
- Bictegravir, emtricitabine, and tenofovir alafenamide
- Drug
- Lead sponsor
- CAN Community Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more